An APOE4 carrier’s guide to clinical trials.

When I got my own APOE 4/4 result, I went looking for clinical trials — and found a wall of clinical language that never answered the one question I actually had: does my genotype even matter for this study? So we built a plain-English read of every Alzheimer’s trial that matters for carriers. This guide is the map that goes with it.

Every trial lists a status. The ones worth your attention are usually Recruiting (actively enrolling) or Not yet recruiting (opening soon). Active, not recruiting means enrollment has closed; Completed or Terminated means it’s over.

See the 757 trials recruiting now →

Phase 1 tests safety and dose in a small group. Phase 2 asks whether it works and is safe — promising, but not proven and not approved. Phase 3 is the large, pivotal test that regulators weigh. Phase 4 is post-approval, real-world monitoring. Many of the most relevant studies for carriers are tagged “NA” — these are lifestyle, cognitive, or observational studies, not drug trials, and they don’t carry a phase.

The newer anti-amyloid antibodies — lecanemab (Leqembi) and donanemab (Kisunla) — can cause ARIA (amyloid-related imaging abnormalities: brain swelling or small bleeds seen on MRI). APOE4 carriers, and homozygous 4/4 carriers most of all, have a higher risk of ARIA — which is exactly why these trials care about genotype, and why several screen or stratify by APOE status. That same genotype sensitivity is why a 4-carrier and a non-carrier can read the same trial very differently. It’s the lens we apply to every study on this site.

This is general education about why genotype appears in trial criteria — not a recommendation for or against any drug. Those decisions belong with your physician.

Every trial page here breaks the sponsor’s own criteria into who the study is looking for and who it can’t include, in plain English — shown exactly as the sponsor wrote them. Skim the exclusions first: a single item (a medication, a prior diagnosis, an MRI contraindication) is often what decides eligibility. The trial site always makes the final call.

• Given my APOE genotype, is an anti-amyloid trial sensible for me — and what’s my ARIA risk?
• Are there prevention or lifestyle studies that fit me better right now?
• What would screening involve, and how far would I travel?

Recruiting now · Browse every hub · All trials

By state: California · Texas · Florida · New York · Massachusetts · Illinois · Pennsylvania · North Carolina · Arizona · Ohio